Abstract | Serotonin (5-HT) has been recognized for decades as an important signalling molecule in the gut, but it is still revealing its secrets. Novel gastrointestinal functions of 5-HT continue to be discovered, as well as distant actions of gut-derived 5-HT, and we are learning how 5-HT signalling is altered in gastrointestinal disorders. Conventional functions of 5-HT involving intrinsic reflexes include stimulation of propulsive and segmentation motility patterns, epithelial secretion and vasodilation. Activation of extrinsic vagal and spinal afferent fibres results in slowed gastric emptying, pancreatic secretion, satiation, pain and discomfort, as well as nausea and vomiting. Within the gut, 5-HT also exerts nonconventional actions such as promoting inflammation and serving as a trophic factor to promote the development and maintenance of neurons and interstitial cells of Cajal. Platelet 5-HT, originating in the gut, promotes haemostasis, influences bone development and serves many other functions. 5-HT 3 receptor antagonists and 5-HT 4 receptor agonists have been used to treat functional disorders with diarrhoea or constipation, respectively, and the synthetic enzyme tryptophan hydroxylase has also been targeted. Emerging evidence suggests that exploiting epithelial targets with nonabsorbable serotonergic agents could provide safe and effective therapies. We provide an overview of these serotonergic actions and treatment strategies.
Introduction
One could argue that we should be using the term enteramine, rather than serotonin, when referring to 5-hydroxytryptamine (5-HT). After all, this substance was first extracted from rabbit gastric mucosa in 1937 by the Italian pharmacologist, Vittorio Erspamer, who named the bioactive amine that he discovered enteramine. 1 About a decade later, Maurice Rapport, Arda Green and Irvine Page of the Cleveland Clinic reported they had isolated a compound from bovine serum that they called serotonin for its vasoconstrictive properties. 2 Within a few years, it was determined that the structure of both of these compounds is 5-HT, and it seems that the second name stuck because it was made available to researchers by Upjohn Pharmaceuticals, who referred to the compound as serotonin. 3 Early on, Erspamer postulated that 5-HT must have an important role in gut function because he detected it in the gastro intestinal tracts of every vertebrate that he studied, from fish to frogs to pigeons to primates, and because he found that the vast majority of 5-HT in the body is synthesized and contained within the gastrointestinal tract. Nevertheless, it is doubtful that Erspamer could have envisioned the variety and broad distribution of 5-HT receptors that are expressed in gastrointestinal tissues, the array of functions that 5-HT serves in the gut, the actions of gut-derived 5-HT outside of the gastrointestinal tract, or the number of serotonergic targets that are in use or in development for the treatment of gastrointestin al disorder s. These are the areas of focus of this Review.
5-HT signalling in the gut
Mucosal 5-HT signalling in the gut The majority of 5-HT in the body is synthesized, stored and released from a subset of enteroendocrine cells, called enterochromaffin cells, in the intestinal mucosa ( Figure 1) . 4, 5 Because the intrinsic and extrinsic afferent nerves of the gut do not reach into the lumen where they could sample for nutrients, toxins or other cues to initiate reflex responses, enterochromaffin cells function as sensory transducers that respond to chemical and mechanical stimuli. 6 Enterochromaffin cells use the ratelimiting enzyme tryptophan hydroxylase 1 (TpH1) in the synthesis of serotonin. 7, 8 As with other types of enteroendocrine cells, the secretory granules of enterochromaffin cells are predominantly located at the basal surface, which is thought to represent the major site of 5-HT release. However, morphological evidence exists for 5-HT release at the apical surface of e nterochromaffin cells, 9 which is consistent with detection of 5-HT release at the mucosal surface using electrochemical techniques. [10] [11] [12] As described in more detail later, 5-HT released from enterochromaffin cells mediates many gastrointestinal functions, including peristalsis, secretion, vasodilation and perception of pain or nausea, through activation of a diverse family of 5-HT receptors on intrinsic and extrinsic afferent nerve fibres that are located in the lamina propria (Figure 2 ). the human colon and, although enterochromaffin cells are obvious, mast cells are not observed. This observation is consistent with the findings of Buhner and Schemann, 13 who also failed to detect 5-HT immunoreactivity in human mast cells. On the other hand, evidence exists that human enteric mast cells express TpH. 14 In addition, in some individuals with mastocytosis, 5-HT levels are increased in a manner that does not correlate with platelet numbers. 15 Interestingly, individuals with mastocytosis who have low levels of circulating 5-HT are more likely to exhibit gastrointestinal and neurological complaints. 16 Regardless, the fact that mast cells in mice express 5-HT indicates that mast cells must be considered as a source of 5-HT in mouse studies, and it is also possible that activated mast cells synthesize and release 5-HT under pathological conditions in humans, c ontributing to conditions such as hypersensitivity.
An important property of intercellular signalling is the termination of the signal by local enzymatic degradation or by uptake into nearby cells or nerve terminals for recycling or degradation. In the case of 5-HT, no intercellular degradative enzymes exist and, as it is a highly charged molecule at physiological pH, it requires a special ized transport mechanism to cross the plasma membrane where it can be degraded by intracellular enzymes such as monoamine oxidase. 17, 18 The s erotoninselective reuptake transporter (SERT), which is also responsible for 5-HT uptake in the brain, is expressed by all epithelial cells of the intestinal mucosa [17] [18] [19] [20] ( Figure 1c ). The serotonin transporter is a member of the neurotransmitter:sodium symporter (NSS) family, TC 2.A.22, which also includes the monoamine transporters DAT (dopamine) and NAT (noradrenaline), and internalizes 5-HT via a sodium-dependent and chloride-dependent mechanism. 21, 22 As all of the epithelial cells in the lining of the intestines seem to express SERT, this transporter serves as a selective sponge to remove 5-HT from the interstitial space after release by entero chromaffin cells. Thus, SERT serves as a critical molecule in the local regulation of 5-HT availability and actions in the intestines. Studies of the intestine during early post natal development, and in adulthood, have demonstrated that decreased SERT function, via reduced expression levels 23, 24 or pharmacological blockade, 24 lead to increased levels of extracel lular 5-HT. Serotonin that is not taken up into the cells of the epithelial lining enters the circulation via the dense capillary bed of the lamina propria, where it is taken up into platelets expressing SERT (Figure 1c) .
Regulation of SERT transcription in the intestinal epithelium differs from that for neuronal SERT. In intestinal epithelial cells, transcription starts downstream from the start site used in neurons, and a region of intron 1 located between these start sites can regulate epithelial SERT expression, but does not affect neuronal SERT expression. 25, 26 Identification of the gut-specific signalling pathways that influence SERT expression and function would make it possible to differentially regulate gut 5-HT signalling with drugs that target the gut epithelium. -HT is released into the interstitial space of the amina propria and binds to receptors on nearby nerve fibres. 5-HT signalling is terminated during the recovery phase: 5-HT is transported by SERT into epithelial cells where it is enzymatically degraded, or it enters the blood stream where it is transported into platelets and stored for future use. b | Immunostaining for 5-HT in a biopsy from the transverse colon of one of the authors (G. M. Mawe). 5-HT is stained blue, and the section is counterstained with the nucleic acid stain, yoyo (green). c | Immunostaining for SERT (red) in a human rectal biopsy specimen demonstrating that essentially all cells in the colonic glands are SERT-immunoreactive. Abbreviations: EC, enterochromaffin; SERT, serotonin-selective reuptake transporter.
Neuronal 5-HT signalling in the gut Although the major depository of the body's 5-HT is the mucosa of the gastrointestinal tract, enteric neurons also express 5-HT. Similar to neurons in the brain, synthesis of 5-HT by enteric neurons is dependent on TpH2. 7, 8 ~2% of neurons in the myenteric plexus are estimated to be serotonergic, 27 and they synapse preferentially, but not exclusively, to other serotonergic neurons, forming a chain of serotonergic interneurons that project d ownstream along the gastrointestinal tract. 28, 29 Studies of stimulus-evoked synaptic responses in the myenteric plexus demonstrate that 5-HT released from these neurons can contribute to both fast and slow e xcitatory postsynaptic potentials (EPSPs). Virtually all evoked fast EPSPs in the enteric nervous system (ENS) are mediated predominantly by acetylcholine acting at nicotinic receptors; however, ~10% of fast EPSPs also include a component sensitive to 5-HT 3 receptor antagonists. 30 The small proportion of fast synaptic events including a serotonergic component corresponds with the small percentage of neurons in the myenteric plexus that express 5-HT, and the small proportion of neurons that are surrounded by 5-HT-immunoreactive nerve terminals. It is reasonable to presume that these synaptic events are involved in descending projections, which is consistent with the finding that descending reflex pathways that ultimately affect circular muscle activity are sensitive to 5-HT 3 receptor inhibition. 31 However, the projection patterns of enteric 5-HT neurons are difficult to reconcile with data showing that inhibition of 5-HT 3 receptors can interrupt ascending contractile reflexes in response to mucosal stimulation. 32 The physiological role of 5-HT-mediated slow EPSPs is less clear, but antagonists of 5-HT 1P 33,34 and 5-HT 7 35 r eceptors can inhibit them.
5-HT signalling in gastrointestinal disorders
Owing to its importance as a signalling molecule in the gut, numerous studies have investigated various elements of mucosal 5-HT signalling in inflamed intestinal mucosa from human biopsies and in animal models of intestinal inflammation. Most studies have reported changes in one aspect or another, and here we highlight the common findings in the context of potential mechanisms underlying the relationship between altered mucosal 5-HT signalling and altered gastrointestinal function and sensation.
Inflammation
Studies investigating mucosal 5-HT signalling have been conducted using human mucosal biopsies from a number of inflammatory conditions, including Crohn's disease, 36, 37 ulcerative colitis, 20,36,37 diverticulitis 38 and active coeliac disease. 39, 40 In patients with ulcerative colitis, 5-HT levels are decreased and there is a trend towards reduced numbers of enterochromaffin cells in the mucosa, although mucosal 5-HT release does not seem to be altered. 20 In coeliac disease, elevations in 5-HT levels, enterochromaffin cell numbers and circulating 5-HT levels have been reported, 39, 40 whereas in diverticulitis, no changes in 5-HT levels or enterochromaffin cell numbers have been detected. 38 Although changes at the upstream end of the mucosal 5-HT signalling pathway vary amongst these inflammatory disorders, all of the conditions described above are associated with decreased epithelial SERT expression levels. Of note, a decrease in SERT has not been detected in inflamed biopsy samples from paediatric patients. 41 5-HT signalling has also been investigated in a number of animal models of intestinal inflammation, including trinitrobenzene sulfonic acid (TNBS)-induced colitis 23 and ileitis 42 in guinea pigs, and TNBS-induced colitis, 25 dextran sodium sulphate (DSS)-induced colitis, 43 Citrobacter rodentium enteritis 44 and Trichinella spiralis enteritis 45 in mice. In all of these conditions, 5-HT levels and e nterochromaffin cell numbers are increased and, where studied, 5-HT release is increased as well. Another consistent feature amongst these models is a decrease in epithelial SERT expression, 23, 25, [42] [43] [44] [45] and it has been demonstrated that this decrease in SERT expression can lead to increased 5-HT availability under both basal and stimulated conditions, 23 supporting the concept that 5-HT signalling is affected by both release and reuptake events.
The findings that mucosal 5-HT content and enterochromaffin cell numbers are increased in animal models of inflammation and in coeliac disease, whereas they are decreased in IBD, might reflect the duration of the inflammatory condition, with animal models and active coeliac disease representing shorter disease duration than chronic IBD. SERT expression is probably downregulated by the inflammatory response; in the Caco-2 human epithelial cell line, SERT mRNA and protein levels, and 5-HT uptake are decreased in an additive manner by treatment with IFN-γ and TNF, or by conditioned medium from activated lymphocytes. 46 Co-culture of Caco-2 cells with E. coli also downregulates SERT expression, 47 and epithelial SERT expression and function in the intestine is decreased in mice infected with enteropathogenic E. coli. 47 Thus, SERT expression and function are downregulated in inflammatory conditions leading to increased 5-HT availability locally and in the circulation.
Functional gastrointestinal disorders
Many features of functional gastrointestinal disorders (FGIDs) are confusing and controversial, and the role of mucosal 5-HT signalling is no exception. IBS is character ized by chronic abdominal pain or discomfort, associated with altered stool frequency or form, in the absence of organic disease that can explain the symptoms. 48 Patients with IBS also typically exhibit a reduced threshold for pain, or visceral hypersensitivity. Owing to the absence of clear pathological markers, as in intestinal inflammation, the diagnosis is made based on the presence of symptoms and further classified by the nature of the predominant stool pattern: IBS-C (constipation), IBS-D (diarrhoea), or IBS-M (mixed or alternating). 48, 49 These subgroups also have physiological relevance as stool consistency (hard to watery) reflects the amount of water absorption as a function of intestinal transit time. 49 
Mucosal 5-HT signalling has been investigated in IBS-D and IBS-C, but not in IBS-M.
Possibly the first molecular alteration reported in the gastrointestinal tracts of individuals with IBS was a decrease in SERT expression in specimens from individuals with IBS-D or IBS-C. 20 These findings led to much discussion and follow-up studies by several groups because it was intuitively difficult to fathom how a decrease in SERT could be associated with the divergen t symptoms of diarrhoea and constipation.
In patients with IBS-D, no differences in basal or stimulated mucosal 5-HT release are detected relative to healthy controls, despite the finding that both mucosal 5-HT content and TpH1 mRNA levels are decreased in these patients. 20 Although Camilleri and colleagues 50 did not detect a change in mucosal SERT mRNA in their population of patients with IBS-D, decreased SERT expression in IBS-D has been reported by others in adults 40, 51 as well as children. 41 In patients with IBS-C, no change in SERT expression was detected in the study by Camilleri.
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As described above, circulating 5-HT comes primarily from the gut and represents the 5-HT that is not captured by SERT in the cells of the epithelial lining. Therefore, circulating 5-HT is often used in studies of gastrointestinal disorders as a reflection of 5-HT availability in the mucosa. Postprandial 5-HT levels are increased in platelet-poor plasma samples obtained from patients with IBS-D [52] [53] [54] or post-infectious IBS 54 , but they have been reported to be reduced 54 or unchanged 53 in IBS-C. By contrast, platelet 5-HT levels are reduced in IBS-D, 55 but in patients with IBS-C they are doubled compared with healthy controls. 53 Collectively, these results are consistent with a decrease in 5-HT uptake by the intestinal epithelium in both of these forms of IBS as it seems that more 5-HT ends up in the circulation. The ability to detect elevated postprandial 5-HT levels in platelet-poor blood in IBS-D, but not IBS-C, might reflect differences in platelet SERT function in these disorders. Uptake of 5-HT into platelets appears to be disrupted in individuals with IBS-D. 40, 55, 56 This disruption could account for the elevated 5-HT in platelet-poor plasma samples from patients with IBS-D, given that 5-HT is normally difficult to detect in such samples, even postprandially. Further studies will be required to determine whether SERT function is altered in the mucosa and/or platelets of individuals with IBS-C.
The pattern of mucosal 5-HT signalling changes that have been detected in chronic constipation differ from those reported in IBS-C or IBS-D, but as in these forms of IBS, the net result seems to be an increase in 5-HT availability. In chronic constipation, SERT expression is not altered, 57 but 5-HT levels, enterochromaffin cell numbers and 5-HT release are increased. 57, 58 The differences in 5-HT fingerprints of these disorders suggest that they represent different entities.
Although mounting evidence strongly supports the concept that mucosal 5-HT signalling is altered in FGIDs, the cause and effect relationship has not been unequivocally resolved. Increasing mucosal 5-HT availability can clearly alter intestinal function. Chronic treatment of mice with the selective serotonin r euptake inhibitor (SSRI) paroxetine decreased stool output and delayed upper gastrointestinal transit, 59 and mice lacking SERT exhibit alternating bouts of diarrhoea and constipation, 19 similar to individuals who suffer from IBS-M. In humans, chronic exposure to SSRIs enhances orocaecal transit, 60 but also can induce constipation by reducing peristaltic activity. 61 On the other hand, acute SSRI administration increases colonic motility and high-amplitude propagated contractions associated with abdominal cramping. 62 These findings suggest that altered mucosal 5-HT signalling could contribute to the symptoms of IBS. Furthermore, changes in gut function are not necessarily associated with changes in the elements of 5-HT signalling as demonstrated in a study of mucosal biopsies in individuals with opiateinduced constipation. 57 In this study, no differences were detected in 5-HT content or release, enterochromaffin cell numbers, TpH1 mRNA or SERT mRNA levels in individuals with opiate-induced constipation compared with healthy controls.
The cause of decreased SERT expression in IBS has not been determined. One possibility is that decreased SERT expression could stem from increased permeability and a related low level of inflammation, as is thought to exist in IBS. 63 Another possibility is that individuals with IBS have a genetic predisposition for decreased SERT expression. A polymorphic region in the human SERT gene (SERT-linked polymorphic region; SERT-LPR), upstream of exon 1a, comprises long (l) and short (s) variants depending on variable numbers of tandem repeats. 64 Interest in this polymorphism was heightened by the finding that, when expressed in lymphocytes, the s/s and l/s genotypes are associated with lower levels of SERT expression and function than the l/l genotype. 64 A possible relationship exists between SERT-LPR alleles and psychiatric disorders, anxiety-related personality traits, suicide, alcoholism and responsiveness to antidepressants. 65 Studies of the SERT-LPR in humans with IBS have demonstrated trends in some populations, but a meta-analysis of these findings failed to detect a clear relationship between the SERT-LPR and IBS, 66 although SERT expression level in the gut does seem to be influenced by the SERT-LPR genotype. 67 Furthermore, a relationship seems to exist between the SERT-LPR genotype and depressive symptoms with IBS-patients with IBS who have the short allele are more likely to have a history of depression. 68 A study of the single nucleotide polymorphism, rs25531, demonstrated that carriers of the rare G allele are three times as likely to have IBS than healthy controls. 69 
Functions of 5-HT in the gut

Conventional actions of 5-HT in the gut
Motility
The concept that 5-HT synthesized and released by enterochromaffin cells in the intestinal mucosa has a role in initiating peristalsis was originally proposed by Edith Bülbring and her colleagues in the late 1950s. [70] [71] [72] [73] Amongst their observations, they found that 5-HT is released by enterochromaffin cells in an i ntraluminal p ressuredependent manner, 72 and that intra luminal infusion of 5-HT restored peristalsis when it had been halted pharmaco logically. 70 Since that time, a number of experimental paradigms, including human prepar ations, have dem onstrated that stroking of the mucosal surface results in 5-HT release. 23, [74] [75] [76] Serotonin release can also be induced by mechanical stimulation of BON cells, a human cell line model of enterochromaffin cells. 77 The elegant studies of groups led by Jack Grider, 78 Terry Smith, 79 and Joel Bornstein 31, 80 have made it clear that 5-HT released in response to mucosal stimulation can activate the ascending contractile and descending relaxant limbs of the peristaltic reflex. Additional support for a role of 5-HT release in propulsive motility comes from ex vivo 23, 78, 81 and in vivo 82, 83 studies demonstrating that antagonists of 5-HT 3 and/or 5-HT 4 receptors slow intestinal motility, as well as a study demonstrating that corticotropin-releasing hormone-induced defecation in rats is reversed by peripheral actions of the 5-HT 3 receptor antagonist, ramosetron. 84 Furthermore, in isolated guinea pig colon preparations, propulsive motility is disrupted by desensitiz ation of 5-HT 4 receptors, 85 or high concentrations of the SERT inhibitor fluoxetine, 17 which presumably leads to 5-HT receptor desensitization by increasing 5-HT c oncentrations in the interstitial space.
In summarizing one of her papers, Edith Bülbring concluded, "Whether 5-HT is of primary importance for the initiation of the peristaltic reflex could not be decided as the amount of 5-HT was never reduced to zero…". 71 New studies once again raise the question of the primary importance of 5-HT in the initiation of peristalsis. Gershon and colleagues 86 demonstrated that intestinal transit and colonic bead expulsion, which presumably involve peristalsis, are unchanged in TpH1 deficient mice. Furthermore, Spencer and colleagues removed the mucosa from mouse and guinea pig colonic preparations and were still able to demonstrate peristalsis activated by stretch of the tissue. 87, 88 On the basis of our current knowledge, it is probably best to conclude that 5-HT released from enterochromaffin cells is sufficient, but not necessary, to initiate the peristaltic reflex.
Another motor pattern that is generated by enteric nerves is segmentation, which consists of alternating contractions of the muscularis in a given region without forward propulsion of the luminal contents. This process serves to mix the contents of the small intestine and maximize their exposure to digestive enzymes during the digestive process. Experimentally, segmentation can be activated by luminal infusion of fatty acids, and a study has demonstrated that mucosal 5-HT is probably involved in the production of this motor pattern. 89 In an ex vivo guinea pig small intestine assay, segmentation was induced by addition of the SERT inhibitor, f luoxetine, and segmentation patterns initiated by fatty acids or fluoxetine were inhibited by antagonists of the 5-HT 3 or 5-HT 4 receptor, as well as by cholecystokinin (CCK) receptor antagonists. 89 The authors therefore concluded that both 5-HT and CCK are involved in the regulation of segmentation motor patterns.
Secretion
In the intestinal epithelium, active secretion can be initiated by intrinsic enteric reflexes that are comprised of primary afferent (sensory) and secretomotor neurons with cell bodies located in nearby submucosal ganglia. 90 The afferent neurons receive signals from projections to the lamina propria and, when stimulated, they synaptically activate secretomotor neurons, which in turn release neurotransmitters such as acetylcholine and vasoactive intestinal peptide (VIP) to activate secretion from the epithelial cells. Serotonin released from enterochromaffin cells is an important activator of these reflex-mediated secretory responses. 77, 91, 92 Mechanical stimulation of the mucosal surface leads to 5-HT release, which activates neurally mediated Cl -and bicarbonate secretion. The neurogenic secretory responses seem to be mediated primarily by 5-HT 3 and 5-HT 4 receptors, but 5-HT 1P receptors might also be involved. 90, 91, [93] [94] [95] [96] [97] Serotonin released from enterochromaffin cells can also stimulate secretion through a direct paracrine action on nearby enterocytes, and this response is mediated by the activation of 5-HT 2 receptors. 94 Serotonin-initiated secretion contributes to the dilution and neutralization of luminal contents, but it is also involved in the protective response to eliminate luminal pathogens.
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Vasodilation Vascular tone is regulated solely by the sympathetic division of the autonomic nervous system throughout most of the body. A unique feature of the gut is the ability of intrinsic reflex circuitry to locally regulate blood vessel diameter. The vasodilatory motor neurons are located in submucosal ganglia, but two types of reflex circuits seem to exist: local circuits (≤2 mm) consisting of afferent (sensory) and motor neurons in the submucosal plexus, and a farther reaching circuit (up to 18 mm) that includes submucosal afferent neurons, projections to the myenteric plexus where signals are passed upstream and downstream along the gut tube, and submucosal vasodilator motor neurons. [103] [104] [105] [106] [107] These reflexes probably involve the same afferent neurons that activate secretomotor responses, and vasodilatory responses that are activated by mucosal stimulation are blocked by in hibition of 5-HT 3 and 5-HT 4 receptors. 96 Activation of extrinsic afferent nerves Early efforts to record from extrinsic afferent fibres innervating the gastrointestinal tract were hampered by the fact that animals were fasted prior to the experiments, and the afferents were quiescent in the absence of the chemical and mechanical stimuli that normally lead to their activation. 108 The first electrophysiological recordings of vagal afferent fibres innervating the gut were accomplished by Autar Singh Paintal in the 1950s. 109, 110 He demonstrated that quiescent sensory fibres innervating the stomach and intestine could be awakened by vascular infusion of phenyldiguanide. This agent, also known as phenylbiguanide, was subsequently shown to be a potent 5-HT 3 receptor agonist.
Vagal afferent fibres arising in the upper gastrointestinal tract send messages that result in a variety of responses upon activation by 5-HT. Pharmacological and immunohistochemical studies have demonstrated that vagal afferent nerve endings in the mucosal layer of the gut express 5-HT 3 receptors. [111] [112] [113] [114] Furthermore, infusion of hyperosmotic solutions or carbohydrate breakdown products into the lumen of the duodenum evokes release of 5-HT from enterochromaffin cells, which acts on 5-HT 3 receptors to stimulate vagal afferent neurons. 115 Glucose in the lumen also causes 5-HT release from enterochromaffin cells, and activates a vago-vagal reflex that inhibits gastric emptying. 116 These stimuli also result in pancreatic secretion, 117 and both the gastric inhibitory response and the pancreatic secretory response are sensitive to 5-HT 3 receptor antagonists. 117 Satiety signals arising from the gut also involve 5-HT releaselipid-induced suppression of food intake is mediated entirely by simultaneous activation of 5-HT 3 and CCK 1 receptors. 118 In humans, inhibition of 5-HT 3 receptors increases the volume of a liquid meal that is ingested, 119 supporting a role for 5-HT receptors and vagal afferent signalling in the regulation of satiety and hunger in humans.
In addition to activation of digestive and homeostatic reflexes described earlier, 5-HT released from enterochromaffin cells in the intestine can lead to feelings of intense discomfort. Cytotoxic chemotherapeutic agents such as cisplatin cause a robust release of 5-HT and activation of 5-HT 3 receptors on vagal afferent fibres resulting in nausea and emesis. [120] [121] [122] How a simple signalling molecule such as 5-HT, acting on one class of receptor, present on the same set of afferent fibres, can lead to such a multitude of reflex responses is hard to imagine. One possible factor in sorting and processing these signals could involve simultaneous activation of vagal afferent nerves that express CCK 1 receptors, which are distinct from those that express the 5-HT 3 receptor. 123 Another contributing factor might be that the amount of 5-HT released in response to chemotherapeutic agents is far greater than that released in response to nutrients and osmotic signals.
Although less is known about 5-HT-induced activation of spinal afferent fibres innervating the gut compared with vagal afferents, in vivo 124 and ex vivo 125 studies of colonic afferent nerves have shown that spinal afferents express 5-HT 3 receptors on their peripheral endings. In studies of noxious colorectal distension in rats, the 5-HT 3 antagonist, alosetron, inhibited reflex responses and c-Fos immunoreactivity in the dorsal horn. 124 Furthermore, the sensitivity of spinal afferents to 5-HT in rats is enhanced during inflammation, both in terms of the proportion of afferent fibres responding to 5-HT and the intensity of the response. 126 This observation is consistent with the finding that the number of nerve fibres expressing 5-HT 3 receptors is increased in the mucosal layer of the DSS-inflamed colon. 127 Interestingly, the hypersensitivity to 5-HT persists after recovery from inflammation, 126 suggesting that the analgesic effect of 5-HT 3 agonists in IBS could involve attenuation of the ability of 5-HT to stimulate spinal afferent terminals in the gut.
Nonconventional actions of 5-HT in the gut
Neuroprotective and trophic factor actions
Given that enteric serotonergic neurons depend on TpH2 for the synthesis of 5-HT, Tph2-deficient mice have been used to investigate the roles of neuronal 5-HT in the bowel. An interesting finding of these studies is that 5-HT seems to be an important factor in the development and survival of enteric neurons. Mice lacking the Tph2 gene exhibit a reduced density of myenteric neurons, particularly dopaminergic and GABAergic nerve cells. 128 These actions of 5-HT might involve the 5-HT 2B receptor, which has been shown to influence enteric neuronal expansion, particularly in the developing gut. 128 Stimulation of 5-HT 2B receptors enhances the differentiation of enteric neurons in cultures from both dissociated cultures of mixed fetal gut cells and in cultures of neural-crest-derived cells isolated from the gut, 129 indicating that 5-HT might influence the fate of developing enteric neurons through actions on 5-HT 2B receptors.
The 5-HT 2B receptor is also expressed by interstitial cells of Cajal (ICC) and is important for the integrity of the ICC network. 5-HT promotes the survival of ICC in culture via actions on 5-HT 2B receptors, 130 and the density of ICC is decreased in 5-HT 2B -receptor-deficient mice. Modelling of these changes suggests that alterations of the ICC network would impair slow wave propagation and ultimately motility and transit in the intestines. 131 The 5-HT 4 receptor also enhances the development and survival of enteric neurons. Studies from 5-HT 4 knockout mice indicate that the density of neurons is not altered at birth, but 5-HT 4 receptor deficiency leads to a postnatal reduction in enteric neurons, and treatment of adult mice with a 5-HT 4 agonist promotes the generation of new enteric neurons. 132, 133 Furthermore, studies of cultured enteric neurons show that stimu lation of 5-HT 4 receptors increases the proliferation and/or survival of enteric neurons and enhances neurite outgrowth. 132, 133 The results of these investigations are supported by the studies of Miyako Takaki and colleagues demonstrating that 5-HT 4 receptor stimulatio n enhances the formation of neural networks in an embryoid body culture system. 134 Activation of 5-HT 4 receptors also leads to regeneration of enteric reflexes and recovery of a d efecation reflex after disruption by colonic resection. 135, 136 TpH2-deficient mice exhibit disrupted intestinal transit. 86 Given these trophic/protective influences of 5-HT on the integrity of the myenteric plexus, it is not clear whether the dysmotility findings from the TpH2 knockout mouse experiments reflect an alteration in serotonergic neurotransmission and/or changes in the circuitry owing to loss of neurons.
Proinflammatory actions of 5-HT in the gut
As described above, 5-HT availability is increased in various animal models of intestinal inflammation, as well as human inflammatory conditions. On the one hand, inflammation is intensified in the IL-10 knockout and TNBS models of colitis when 5-HT availability is increased by lack of the 5-HT transporter in SERT deficient mice. 137, 138 On the other hand, the extent of inflammation in DSS and DNBS colitis models is reduced when mucosal 5-HT availability is reduced by deletion of the gene that encodes TpH1 or by reduction of 5-HT synthesis with parachlorophenylalanine. 139 Bypassing TpH1 in TpH1-deficient mice by treatment with the 5-HT precursor, 5-hydroxytryptophan increased the severity of colitis in these animals. The proinflammatory actions of 5-HT in the mucosa involves a chain of events that are probably initiated by activation of 5-HT receptors on dendritic cells in the lamina propria. 140 
Distant actions of gut-derived 5-HT
It has long been generally accepted that 'virtually all' peripheral 5-HT arises from the gut. This notion is based on the early studies of Erspamer and Bertaccini who demonstrated that total gastroenterectomy in rats or dogs caused a disappearance of the metabolite 5-hydroxyindoleaceti c acid from the urine, and markedly lowered 5-HT levels in the blood, spleen and lungs. 141, 142 They also demonstrated that 5-HT levels in portal venous blood were much higher than in vena cava blood in these animals. On the basis of these findings, and the ability of SERT-expressing platelets to distribute 5-HT throughout the body, it has been presumed that noncerebrospinal actions of 5-HT outside the gut involve 5-HT arising from enteric enterochromaffin cells.
Many tissues express 5-HT receptors, and actions of 5-HT outside the gut include vasoconstriction or vasodilation (depending on the vascular bed), platelet aggregation, haematopoiesis, regulation of bone density, bronchoconstriction, itching sensation and n ociception. 143 Furthermore, 5-HT seems to be involved in heart and mammary development, as well as oocyte maturation. 143 The role of 5-HT in decreased bone density and allergic airway inflammation is of particular interest because TpH inhibitors have been tested as a therapeutic strategy for these conditions.
Low density lipoprotein receptor-related protein 5 (LRP5) is a Wnt co-receptor that is important in the control of bone density, and evidence indicates that it affects bone indirectly through regulation of 5-HT synthesis by enterochromaffin cells. 144 In Lrp5-deficient mice, TpH1 expression and mucosal 5-HT concentrations are elevated. Increased 5-HT levels decrease bone formation by interacting with 5-HT 1B receptors to inhibit osteoblast proliferation. Inhibition of TpH1 has been shown to have protective action in an ovariectomy model of osteoporosis, further supporting a role for 5-HT as a regulator of bone growth and density. 145 A role for 5-HT in the manifestation of allergic airway inflammation has been well established, yet the source of the 5-HT was not clearly defined, and it was not known whether TpH1 was involved in synthesis of that 5-HT. Idzko and colleagues have now demonstrated that platelets provide the 5-HT that contributes to asthma pathogenesis, and that symptoms in a mouse model of allergic airway inflammation are greatly reduced in TpH1-deficient mice or mice treated with a TpH1 inhib itor. 146 These findings indicate that the 5-HT that interacts with airway tissues during asthma attacks originates in the gut, and that TpH1 inhibitors acting in the gut could provide a novel therapeutic approach for the t reatment of asthma.
Although most, if not all, platelet serum probably arises in the gut, evidence indicates that TpH1 expression can be activated locally in a variety of tissues. 147 For example, considerable controversy exists as to whether gut-derived 5-HT and/or 5-HT from local TpH1-expressing osteoclasts regulate bone remodelling by affecting both osteoclast and osteoblast development. 148 Furthermore, mouse mammary epithelium expresses mRNA for the 5-HT synthetic enzymes TpH1 and aromatic amine decarboxylase when stimulated by prolactin, 149 and cells expressing TpH1 in the placenta give rise to 5-HT that is crucial for brain development. 150 Regardless of the source of 5-HT regulating these systems under normal circumstances, pharmacological interventions and pathological conditions that affect gut 5-HT signalling, and ultimately circulating 5-HT levels, have the potential to affect many other tissues. 
Therapeutic serotonergic targets
5-HT 3 receptors
Owing to their value as a therapeutic target in the gut, 5-HT 3 receptors have been investigated extensively. They are expressed on the excitable cells of the gut, including intrinsic and extrinsic afferent nerves that extend into the mucosa, interneurons, inhibitory and e xcitatory motor neurons, ICCs, smooth muscle and enterocytes ( Figure 3 ). As described above, 5-HT 3 receptors are involved in the activation of intrinsic and extrinsic afferent nerves by 5-HT released from entero chromaffin cells, and they contribute to a small subset of EPSPs. In an elegant and technically difficult investigation, Bertrand and colleagues demonstrated that AH neurons in the myenteric plexus, which serve as primary afferent neurons and project to the mucosa, are directly activated by 5-HT applied to the mucosa, and that these responses are exclusively mediated by 5-HT 3 receptors. 152 Initial therapeutic use of 5-HT 3 receptor antagonists arose from the landmark discovery in 1986 that specific 5-HT 3 receptor antagonists could inhibit cisplatin-induced emesis.
153,154 5-HT 3 receptor antagonists probably exert their antinausea effects via at least two sites of action (vagal afferents in the gut and in the area postrema), and they are particularly effective in treating the acute phases of c hemotherapy-induced and radiation-therapy-induced nausea and emesis. 121, 122 A common adverse effect of using 5-HT 3 receptor antagonists for anti nausea and antiemetic purposes is constipation, and this action has been exploited for the treatment of IBS-D. 83, 155 5-HT 3 antagonists have been shown to be effective in treating both the diarrhoea and abdominal discomfort symptoms of IBS-D. 156, 157 Although the precise mecha nisms of action of 5-HT 3 antagonists have not been definitively determined, it is possible that they inhibit 5-HT 3 receptors located on intrinsic and extrinsic afferent nerve fibres in the mucosa that are activated by 5-HT released from enterochromaffin cells. They also inhibit the stimulation of 5-HT 3 receptors on inter neurons and motor neurons that contribute to fast EPSPs. 30 Collectively, these actions would decrease propulsive motility and secretion locally within the gut, thus allevi ating diarrhoea, as well as decreased signalling from spinal afferent nerves that deliver signals of pain and discomfort to the CNS. As described above, the 5-HT 3 antagonist, alosetron, inhibits activation of dorsal horn neurons in response to noxious distention of the ; 5-HT 2B 129,130,192-194 ; 5-HT 3 33,74,81,106,112,116,117,119,123,124,152,186 ; 5-HT 4 11,74,133,168,170,171,173,186,195 ; 5-HT 7 35, 196 .
REVIEWS colon, 124 indicating that 5-HT 3 receptors are involved in the activation of pain signals from the gut. However, the vi scero-analgesic benefits of 5-HT 3 antagonists might also involve central mechanisms of action. 158 With the knowledge that 5-HT 3 receptors can participate in the activation of propulsive motility and secretory responses in the gut, 5-HT 3 agonists have been developed and tested for the treatment of constipation. Efforts have been concentrated on partial agonists because 5-HT 3 receptors desensitize rapidly and, as outlined above, stimulation of 5-HT 3 receptors on vagal and spinal afferent fibres can lead to nausea and abdominal discomfort, respectively. One such compound is pumosetrag, which is being developed for the treatment of IBS-C and has also been shown to reduce reflux events in individuals with GERD. 159, 160 Another, somewhat counterintuitive strategy, is to use a high affinity, low intrinsic activity 5-HT 3 receptor partial agonist for the treatment of IBS-D. 160 The concept being proposed is that these compounds would interrupt activation of 5-HT 3 receptors by excessive background levels of 5-HT, such as those that are thought to exist in IBS-D, while enabling the receptors to be activated during reflex responses, thus reducing the chance of developing constipation.
5-HT 4 receptors
Agonists of the 5-HT 4 receptor alleviate constipation in IBS-C and in chronic constipation, provide pain relief in IBS-C, and accelerate the rate of gastric emptying. [161] [162] [163] [164] Benzamides, such as metoclopramide, cisapride and renzapride, were recognized as prokinetic agents in the gut even before the existence of 5-HT 4 receptors was discovered; they were initially considered cholinergic compounds because they enhance acetylcholine release from myenteric neurons. 165, 166 However, soon after the discovery of 5-HT 4 receptors, it was determined that benzamides are 5-HT 4 receptor agonists, and efforts were made to determine the mechanisms by which they promote motility. Considerable physiological data suggest that 5-HT 4 receptor stimulation accelerates the peristaltic reflex. 11, [167] [168] [169] Furthermore, transgenic mice that lack 5-HT 4 receptors exhibit slowed colonic motility, 133 suggesting that 5-HT 4 receptors are physiologically activated and contribute to the regulation of propulsive motility and/or they promote normal motility through their trophic actions mentioned above. Within the muscularis externa, 5-HT 4 agonists act presynaptically on nerve terminals to enhance the release of acetylcholine. [169] [170] [171] [172] [173] By acting in this manner, they are thought to enhance naturally occurring reflex activity rather than to generate neurotransmission. This distinction is important because efficient propulsive motility is a complex and carefully orchestrated process, and simply activating transmitter release by neurons throughout the gut tube actually inhibits propulsive motility. 174 Unfortunately, although shown to be effective, the 5-HT 4 agonists that were initially made available for the treatment of constipation, cisapride and tegaserod, were ultimately removed or restricted because of potential cardiovascular adverse effects. The adverse effects of the early 5-HT 4 compounds are thought to be related to their relative lack of selectivity and resultant actions on other targets, including hERG potassium channels, dopamine receptors and 5-HT 1 and 5-HT 2 receptors. 175, 176 Therefore, more selective agonists such as prucalopride, naranopride (ATI-7505), mosapride and velusetrag (TD-5108) are becoming available or are being developed to fill this gap. 176 We have published the results of a study that reveals a novel target for 5-HT 4 agonists that could provide clinical benefits while minimizing the risk of adverse effects.
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In ex vivo motility and peristaltic reflex assays, we and others found that 5-HT 4 agonists accelerate propulsive motility when they are infused into the lumen or applied to the mucosal surface; 11, 78, 168, 177 however, addition of a gonists to the bathing solution where they would be in a position to access the nerve terminals of the peristaltic reflex circuitry did not enhance motility. 11 These results suggest the existence of 5-HT 4 receptors in the mucosa. Evaluation of fluorescence in a strain of mice in which the promoter of the gene encoding 5-HT 4 drives the expression of enhanced green fluorescent protein revealed that essentially all of the cells of the colonic mucosa express the 5-HT 4 receptor (Figure 4 ). Additional studies dem onstrated the presence of transcript for this receptor in the colonic mucosa of mice, rats and humans. 11 Furthermore, mucosal application of 5-HT 4 agonists activated 5-HT release from enterochromaffin cells, mucus discharge by goblet cells and Cl -secretion by enterocytes; 5-HT 4 receptor antagonists blocked these actions. Any or all of these actions could alleviate constipation, and formulating 5-HT 4 agonists such that they target the colon without being absorbed could result in a safe and effective t reatment of IBS-C and chronic constipation.
A welcome, but puzzling, action of 5-HT 4 receptor agonists is that they attenuate visceral pain arising from the colon. In humans, oral administration of the 5-HT 4 receptor agonist tegaserod reduced rectal sensitivity to distension in individuals with IBS. 178 Furthermore, intraperitoneal or intraluminally administered te gaserod attenuated nociceptive responses in a visceral hyper sensitivity model involving awake, freely moving rats. 11, 179 The reason this action is puzzling is that 5-HT 4 receptor stimulation leads to activation of the cyclic AMP-protein kinase A pathway, which has an excitatory effect on neuro nal activity, as is seen with the presynaptic facilitatory actions of 5-HT 4 agonists. It has been proposed that the antinociceptive actions of these compounds involve their nonselective inhibitory action on 5-HT 2B receptors, but the actions of tegaserod in these studies are blocked by 5-HT 4 receptor antagonists. 11, 180 Furthermore, intraluminal administration of the selective 5-HT 4 receptor antagonist ATI-7505 inhibits visceral hypersensitivity. 11 One possible mechanism by which 5-HT 4 receptors could attenuate visceral nociception is through an inhibitory action on intramural mechanoreceptor activation; in a rectal distension study in cats, tegaserod decreased afferent discharge at nociceptive intraluminal pressures without altering compliance. 181 However, even if mechanoreception is inhibited by 5-HT 4 agonists, the precise mechanism of this inhibition has not been clearly determined.
Tryptophan hydroxylase
Substantial evidence indicates that 5-HT released from enterochromaffin cells can activate enteric secretory and motor reflexes, as well as send signals to the CNS. Therefore, it stands to reason that suppressing this signalling apparatus by decreasing 5-HT release could possibly attenuate the symptoms of IBS-D. Accordingly, efforts have been made to develop TpH inhibitors that decrease gastrointestinal 5-HT levels without affecting s erotonergic signalling in the brain by limiting their ability to cross the blood-brain barrier. [182] [183] [184] Results of a double-blind, placebo-controlled study of one of these compounds, LX-1031, indicate that this approach shows promise for treating the symptoms of non-constipating IBS. 183 In this 4 week trial, LX-1031 resulted in substantial relief of pain and discomfort, and in improvement of stool consistency. Treatment with the TpH inhibitor decreased peripheral 5-HT levels, as reflected by dose-dependen t decreases in urine levels of the 5-HT metabolite, 5-HIAA. Interestingly, a correlation between symptom i mprovement and r eduction in 5-HIAA levels was noted.
Conclusions
Despite our best efforts over the past six decades to understand 5-HT signalling in the gut, many u nanswered questions remain and new questions are still arising. That 5-HT has a role in many g astrointestinal functions and in sending signals from the gut to the CNS is generally accepted. In addition, drugs that target 5-HT signalling molecules are clearly effective at alleviating the symptoms of FGIDs. Identifying sub populations of individuals with a given type of IBS who will respond best to these treatments is an important goal. One feature of 5-HT biology that we have not extensively addressed in this Review is the interrelationsh ip between genetic polymorphisms in the genes of 5-HT signalling molecules and various forms of IBS. No clear answers have yet emerged for this issue, but it is important to keep trying. Another important goal is to understand more precisely the distributions of 5-HT receptors and to determine which receptors in what locations are physiologically relevant. Much of our information is from whole organ or in vivo assays with which it is impossible to resolve the precise locations of receptors involved in a given reflex response. Gaining answers to these questions will require labourintensive, low-throughput approaches such as those used by Bertrand and colleagues to demonstrate that 5-HT 3 receptors are located on mucosal projections from myenteric primary afferent neurons. 152 Another emerging feature of 5-HT signalling is that most of the targets of therapies for FGIDs are expressed by epithelial cells or within 20 μm of the epithelial surface. These targets include TpH1, as well as 5-HT 3 and 5-HT 4 receptors. Attempting to reach these receptors directly, rather than via the systemic circulation, could greatly improve the benefit:risk ratio for these treatments.
Review criteria
In the process of preparing this Review we used our collective 35 years of experience studying serotonin signalling and serotonin receptors in the gastrointestinal tract, and we conducted a number of literature searches. PubMed database searches involved combinations of terms that included "serotonin", "SERT", "tryptophan hydroxylase", "receptor", "inflammation", "IBS", "motility", "secretion", "vagal afferent", "spinal afferent", "intrinsic afferent", "AH neuron", "gastrointestinal", "intestine", "stomach", "colon" and "enteric nervous system".
